BioIVT was a proud sponsor of the 25th North American ISSX Meeting. We’re looking forward to reconnecting with you, hearing about your challenges, and discussing how our products and services can help accelerate your drug discovery and ADME-Tox programs.
 
See the list of all of our scientific contributions at the event: 

• POSTER SESSIONS
  
  
  • Impact of Donor Diversity on Phase I and Phase II Activities in Cryopreserved Hepatocytes and Human Liver Microsomes
    Presented By: Chris Bohl, PhD, Scientific Advisor, Products, BioIVT
    
    
  • Monocarboxylate Transporter 10: Substrate-Dependent Mode of Transport
    Presented By: Mark Warren, PhD, Senior Dir. of Transporter Assay Services, BioIVT
    
    
  • Development of a Simple, Fast Inhibition Assay for Rat CYP3A Enzymes
    Presented By: Michael Voice, PhD, General Manager, Operations, BioIVT
    
    
• INDUSTRY-SPONSORED SYMPOSIUM
  
  
  • Title: Highlights of the In Vitro Sections of the Draft ICH Drug Interaction Studies M12 Guideline and Comparison with Current Guidance
    Presented by: Brian Ogilvie, VP, Scientific Consulting, BioIVT
    
    
  • Abstract: In June 2022, the ICH released the draft of its harmonized Drug Interaction Studies Guideline (M12).  The guideline resulted from several meetings of the Expert Working Group since 2018 with the goal of harmonizing member regulatory agencies’ guidelines into one that will be used across all member countries. After review, the guideline will be adopted in 2024. This presentation will describe differences between current in vitro drug-drug interaction guidance from the relevant US FDA, EMA and PMDA guidance documents, and how to plan on meeting the ICH M12 guideline.